{"0": ["new", "york", "nov", "prnewswire", "reportlinker.com", "announces", "new", "market", "research", "report", "available", "catalogue", "pharma", "leader", "series", "top", "biosimilar", "drug", "manufacturers", "2013-2023", "http://www.reportlinker.com/p01861536/pharma-leader-series-top-25-biosimilar-drug-manufacturers-2013-2023", "related", "links", "http://www.reportlinker.com", "new", "york", "nov", "prnewswire", "reportlinker.com", "announces", "new", "market", "research", "report", "available", "catalogue", "pharma", "leader", "series", "top", "biosimilar", "drug", "manufacturers", "2013-2023", "http://www.reportlinker"], "1": ["narayanan", "oration-crawford", "school", "public", "policy-anuthe", "narayanan", "oration", "presented", "australia", "south", "asia", "research", "centre", "year", "lecture", "delivered", "kiran", "mazumdar-shaw", "chairperson", "managing", "director", "biocon", "limited", "india", "biocon", "malaysia", "biocon", "fortunate", "\u202a", "\u200e", "science", "\u202c", "cannot", "explain", "everything", "look", "future", "touching", "story", "\u202a", "\u200e", "cancer", "\u202c"], "2": ["kiran", "mazumdar-shaw", "kiran", "mazumdar-shaw", "born", "march", "indian", "entrepreneur", "chairman", "managing", "director", "biocon", "limited", "biotechnology", "company", "based", "bangalore", "bengaluru", "india", "current", "chairperson", "iim-bangalore", "awarded", "othmer", "gold", "medal", "outstanding", "contributions", "progress", "science", "chemistry", "kiran", "mazumdar-shaw", "started", "corporate", "social", "responsibility", "wing", "biocon", "biocon", "foundation", "foundation", "focuses", "areas", "health", "education", "infrastructure", "especially", "rural", "areas", "karnataka", "lack", "healthcare", "facilities"], "3": ["biocon", "milestone", "events", "year", "follows", "november", "\u2014", "biocon", "india", "incorporated", "joint", "venture", "biocon", "biochemicals", "ltd", "ireland", "kiran", "mazumdar-shaw", "\u2014", "becomes", "first", "indian", "company", "manufacture", "export", "enzymes", "usa", "europe", "novel", "licensing", "program", "biocon", "programs", "out-license", "two", "molecules", "t1h", "positive", "safety", "clearance", "profile", "orally", "delivered", "conjugated", "insulin", "drug", "expected", "market", "soon", "currently", "undergoing", "phase", "clinical", "studies", "india"], "4": ["biocon", "entered", "2,200", "high-value", "r", "licensing", "deals", "within", "pharmaceuticals", "bio-pharmaceutical", "space", "also", "expanded", "global", "footprint", "emerging", "developed", "markets", "acquisitions", "partnerships", "in-licensing", "novel", "licensing", "program", "biocon", "programs", "out-license", "two", "molecules", "t1h", "positive", "safety", "clearance", "profile", "orally", "delivered", "conjugated", "insulin", "drug", "expected", "market", "soon", "currently", "undergoing", "phase", "clinical", "studies", "india"], "5": ["biocon", "first", "biotechnology", "company", "india", "issue", "ipo", "biocon's", "ipo", "oversubscribed", "times", "first", "day", "bourses", "closed", "market", "value", "1.11", "billion", "making", "biocon", "second", "indian", "company", "cross", "billion", "mark", "first", "day", "listing", "kiran", "mazumdar-shaw", "started", "corporate", "social", "responsibility", "wing", "biocon", "biocon", "foundation", "foundation", "focuses", "areas", "health", "education", "infrastructure", "especially", "rural", "areas", "karnataka", "lack", "healthcare", "facilities"], "6": ["www.bioconacademy.com", "write", "admissions@bioconacademy.com", "biocon", "driven", "passion", "develop", "research-driven", "cutting", "edge", "therapies", "tryst", "innovation", "enabled", "us", "address", "relatively", "unmet", "needs", "patients", "differentiated", "products", "challenging", "therapeutic", "spaces", "earned", "trust", "patients", "doctors", "products", "safe", "efficacious", "affordable", "constantly", "engaged", "pursuit", "excellence", "find", "solutions", "heal", "world", "biocon", "india's", "largest", "fully-integrated", "innovation-led", "biopharmaceutical", "company", "largest", "indian", "insulins", "company", "believe", "made", "huge", "difference", "millions", "diabetic", "patients", "india", "years", "biocon", "also", "emerged", "leading", "indian", "oncology", "company", "making", "cancer-care", "affordable", "accessible"], "7": ["biocon", "limited", "bse", "indian", "biopharmaceutical", "company", "based", "bangalore", "india", "company", "manufactures", "generic", "active", "pharmaceutical", "ingredients", "apis", "sold", "developed", "markets", "united", "states", "europe", "novel", "licensing", "program", "biocon", "programs", "out-license", "two", "molecules", "t1h", "positive", "safety", "clearance", "profile", "orally", "delivered", "conjugated", "insulin", "drug", "expected", "market", "soon", "currently", "undergoing", "phase", "clinical", "studies", "india"], "8": ["biocon", "biocon", "pharmaceuticals", "sector", "current", "market", "capitalisation", "stands", "rs", "8,773", "crore", "company", "management", "includes", "kiran", "mazumdar", "shaw-chairperson", "managing", "director", "john", "shaw-vice", "chairman", "arun", "chandavarkar-joint", "managing", "director", "ceo", "charles", "l", "cooney-non", "exe", "ind"]}